b‑lymphocyte targeting agents for use in methods of treatment of disease
A technology of lymphocytes and cells, applied in the direction of disease diagnosis, allergic diseases, cardiovascular system diseases, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0107] Example 1: Detection of B-lymphocytes in patients with cardiac insufficiency
[0108] Endomyocardial biopsies were taken from the RV septum, frozen in liquid nitrogen and stored at -80°C. Embed the sample in Tissue Tec (SLEE, Mainz, Germany) and immediately snap-frozen in liquid nitrogen-cooled methylbutane. Embedded samples were serially cut into 5 μm thick cryosections and placed on slides precoated with 10% poly-L-lysine. After fixation in cold acetone for 10 min followed by air drying, cryosections were 2 o 2 A solution in phosphate-buffered saline was incubated for 20 minutes to inhibit endogenous peroxidase activity.
[0109] For immunohistostaining, CD20 monoclonal mouse antibody clone 8J662 (Fa. Biomol, Hamburg, Germany) was used for 45 min in a humidified chamber. In the humidified chamber, the EnVision TM Peroxidase-conjugated rabbit anti-mouse antibody (DakoCytomation, Hamburg, Germany) was used as secondary antibody for 30 min. Immunohistological sta...
Embodiment 2
[0112] Example 2: Treatment of Male Inflammatory Dilated Cardiomyopathy (DCMi) Patients
[0113] A 76-year-old male patient with a 3-year history of cardiac insufficiency (caused by DCMi) was treated with Rituxan using the manufacturer's recommended dosing regimen (end-stage DCM, severe DCMi; mild cardiac inflammation, absence of cardiac virus, cardiac biopsy sample Medium is CD20 positive, NYHA III, EF 20%; LVEDD71mm). Symptoms and LV function (EF 29%) had improved 24 hours after the first single dose of Rituxan and remained stable after the second Rituxan administration as per protocol. Stress echocardiography showed an improvement in LV functional reserve as well, compared with the examination performed before the application of Rituxan.
Embodiment 3
[0114] Example 3: Treatment of Female Patients with Inflammatory Dilated Cardiomyopathy (DCMi)
[0115] The patient was a 73-year-old woman with a 5-year history of heart failure symptoms caused by severe dilated cardiomyopathy (EF 24%) despite use of heart failure medications and biventricular ICD stimulation (NYHA class III) keep showing up.
[0116] With heart failure drugs and 375mg / m 2 Rituxan (rituximab) for body surface area treated this female patient in two phases.
[0117] Echocardiography showed a significant increase in left ventricular ejection fraction (LVEF) after the first dose of Rituxan and a further increase after the second dose of Rituxan ( image 3 A). At the same time, the left ventricular end diastolic diameter (LVEDD) decreased ( image 3 B). In Table 1 the individual measured values are listed.
[0118] After treatment with Rituxan, BNP levels were significantly reduced ( Figure 4 A).
[0119] Rituxan treatment also improved patients' perfo...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More